AMAG Pharmaceuticals Just Filed Its Quarterly Report: The components of b...


The components of basic and diluted net loss per share were as follows (in thousands, except per share data):

 

 

 

Three Months Ended March 31,

 

 

 

2014

 

2013

 

Net loss

 

$

(7,102

)

$

(3,895

)

Weighted average common shares outstanding

 

21,824

 

21,544

 

Net loss per share:

 

 

 

 

 

Basic and diluted

 

$

(0.33

)

$

(0.18

)

 

The above information was disclosed in a filing to the SEC. To see this filing in its entirety, click here.

To receive a free e-mail notification whenever AMAG Pharmaceuticals makes a similar move, sign up!

Other recent filings from the company include the following:

Amag Pharmaceuticals To Acquire Lumara Health Maternal Health Business - Sept. 29, 2014
Registration of securities [Section 12(b)] - Sept. 29, 2014
AMAG: Iv. The Terms Of Stipulation And Agreement Of Settlement - Sept. 12, 2014
Amag Pharmaceuticals Announces Appointment Of John A. Fallon, M.D. To Board Of Directors - Sept. 8, 2014
AMAG Pharmaceuticals director just declared 0 ownership of the company. - Sept. 8, 2014

   Auto Refresh

Feedback